Intelomed

Intelomed is developing a non-contact patient-monitoring device to improve telehealth treatment outcomes. Using only the camera of a smartphone, mCVInsight (Mobile Cardiovascular Insight) will measure the micro-changes of color of a patient’s face in order to provide clinicians with valuable diagnostics and patient data in real-time. Intelomed is currently in-market with previous patient-monitoring technology and is actively working to secure FDA-clearance for mCVInsight. Intelomed's mCVInsight is currently in the prototype stages of development.

Select this bonus

$100+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.




Select this bonus

Friends and Family Early Birds
Invest within the first 72 hours and receive 15% bonus shares




2
days

11
hours

57
mins

0
secs





Select this bonus

$1,000+ Investment
Tier 1 Perk
Invest $1,000+ , receive additional 2% bonus shares


Select this bonus

$5,000+ Investment
Tier 2 Perk
Invest $5,000+ , receive additional 5% bonus shares


Select this bonus

$10,000+ Investment
Tier 3 Perk
Invest $10,000+ , receive additional 10% bonus shares


Select this bonus

$25,000+ Investment
Tier 4 Perk
Invest $25,000+ , receive additional 15% bonus shares

Intelomed has designed a remote system for easily obtaining patient vital signs using only a smartphone. We believe this real-time, data-based approach has the potential to drastically improve treatment capabilities and overall quality of care within the telemedicine industry.

As the landscape of healthcare increasingly shifts towards telehealth-based medicine, we believe there is more market opportunity than ever before. Valued at $90B in 2021, the global telehealth market is projected to grow rapidly to $636B by 2028 with a CAGR of 32.1%.*

The Intelomed team has been developing advanced patient-monitoring technology since 2005. Our previous product was granted FDA-clearance & has been successful in improving patient outcomes in the dialysis clinic treatment setting. We plan to leverage this experience as we work to secure FDA-clearance for our new technology, mCVInsight.

William P. Malloy



CEO & Board member


Bill has served as the CEO of InteloMed since 2017 and has served on its Board of Directors since 2011. He also serves as the Chairman of the Board and President of ROAM Holdings, LLC, a passive holder of three real estate properties in Western Pennsylvania. Prior to his position at ROAM Holdings, Bill served as the Director of the Saint Vincent Archabbey and Seminary Development Office and was President of First Bank of Leechburg.
Bill is an active community volunteer, offering his time and experience by serving as the Board Chairman of Adelphoi USA, the Adelphoi Foundation and Homes Build Hope, which provides affordable housing to low-income residents of Westmoreland County. He previously served as the Chairman of the Board of the Westmoreland County Chapter of the American Red Cross, the Northside Community Development Fund, and the Northside Micro-Enterprise Fund.
William P. Malloy is full-time at Intelomed; 40-50 hours per week.















Mark Rossi



Board chairperson


Mark joined the Intelomed Board in 2011 and was elected Chairman in 2013.
Mark has served on the Board of Directors of numerous public and private companies, including as Board Chairman of Cardtronics (CATM) which was acquired by NCR in 2021 and of Maxwell Technologies (MXWL) which was acquired by TESLA in 2019. In addition to Intelomed, he currently serves on the boards of Vali Security, Inc, a cyber security company focused on the LINUX operating system and OcuDoc, Inc, a telemedicine company focused on vision care.
Mark was a Founding partner of Cornerstone Equity Investors and was President of Prudential Equity Investors, the private equity arm of Prudential Financial, Inc.
Mark holds a Masters Degree from the Kellogg School of Management of Northwestern University and a Bachelors Degree in Economics from Saint Vincent College.
Mark Rossi is part-time at Intelomed; 1-2 hours per week.















R. Stephen Doyle



Board member


Stephen has served as a member of InteloMed Board of Directors since June 2014.
In 1974, Stephen began his career at E.F. Hutton & Co. and later joined Montgomery Securities. In 1990, he became the founder, chairman and CEO of Montgomery Asset Management, an independent affiliate of Montgomery Securities. Stephen also served as Chairman of the Board of Trustees of the Montgomery Funds, a $5 billion mutual fund complex. In 1997, he successfully negotiated the sale of Montgomery Asset Management to Commerzbank, Germany’s third largest bank. He continued to serve as Chairman and CEO of Montgomery Asset Management until May 2001 and as Chairman Emeritus until December 2001.
Stephen currently serves as the Chairman of the Board of Innisfree Investments, LLC. He serves as an emeritus board member of The Basic Fund, a charitable organization located in San Francisco.
Stephen is a graduate of Menlo College and San Jose State University and served in the United States Marine Corps.
R. Stephen Doyle is part-time at Intelomed; 1-2 hours per week (limited to participation in board activities).















Jill Schiaparelli



Board member


Jill joined the InteloMed Board of Directors in April 2015 and served as President and CEO from July 2015 until May 2017. Jill has more than 20 years of global experience in health care innovation, strategy and commercialization.
She has launched multiple medical device and biotech products and has held senior leadership positions with major healthcare companies such as Johnson & Johnson and Baxter and has served as an executive at high-growth biotech companies such as ApaTech (UK) (sold to Baxter) and AxoGen.
Jill currently serves as the President and CEO of Avation Medical, a venture-backed medical technology company making neuromodulation more accessible to patients as a treatment for a wide variety of clinical conditions. Jill is also a founding partner in JS Strategic Partners, a strategic consulting group to help young companies bring innovative technologies to market. Her early career was spent in investment banking and finance.
Jill received her MBA from the Stern School of Business at New York University and a Bachelor of Science in Business Administration from Boston University.
Jill Schiaparelli is part-time at Intelomed; 1-2 hours per week (limited to participation in board activities).















Ned Laubacher



Board member


Ned Laubacher has spearheaded growth strategies and financial turnarounds throughout his career as both a CXO and strategic advisor to health networks and major employers. Ned’s experiential knowledge is sought to position organizations for long-term growth, financial strength, and reputational excellence. He is also serving as the interim CEO of a senior care continuum with seven operating divisions. Ned’s subject matter expertise in business analytics and growth strategies are the core of his consulting services.
Ned also responds to the clinical needs within the healthcare industry by advising biomedical start-up companies from idea to launch, encompassing research testing, engineering design, supplies sourcing, contract manufacturing, and market sales pathway.
Ned holds dual masters’ degrees from the Anderson School of Management and the Fielding School of Public Health at the University of California, Los Angeles.
Ned Laubacher is part-time at Intelomed; 1-2 hours per week (limited to participation in board activities)